Best disease, also known as vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and ...
An expert summarizes real-world GA management lessons, highlighting personalized imaging-guided care and patient-centered strategies to maintain vision stability. Dr. Sambhara closes with ...
A panelist discusses how careful timing, patient education, and bilateral treatment planning strengthen real-world NT-501 management for MacTel type 2. A panelist discusses how key takeaways from ...
A panelist discusses how strategic eye selection and proactive patient counseling optimize success and satisfaction with NT-501 implantation for bilateral MacTel type 2. A panelist discusses how ...
A panelist discusses how evolving imaging and the approval of NT-501 therapy are transforming macular telangiectasia type 2 from a diagnostic challenge into a treatable condition. A panelist discusses ...
A panelist discusses how individualized imaging-based decisions guide when to initiate NT-501 therapy in both early and advanced stages of MacTel type 2. A panelist discusses how selecting the first ...
Stephen Tsang, MD, PhD, reviews promising optogenetic therapy results for retinitis pigmentosa and Stargardt disease, enhancing vision and mobility for patients.
Sharon Fekrat, MD, FACS, FASRS, shares insights on the retinal manifestations of antipsychotic medications.
EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME ...
Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of Ophthalmology Times for more than 20 ...
Aviceda Therapeutics has completed enrollment of the phase 2b trial of the SIGLEC Study. The study will assess the safety and efficacy of AVD-104, the company’s formulation designed to treat ...
Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics). Ahead of the Clinical Trials at the Summit (CTS) meeting in Las ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback